

VPA22812/003/001

Butasal 100 mg/ml + 0.05 mg/ml solution for injection for horses, cattle, dogs and cats

Variation	Summary	Date
Vet - B12 a)	VNRA - Vet - B12 a) - - Vet - B12 a) - Minor changes:— to an approved test procedure — for active substance or a starting material, reagent or intermediate used in the manufacturing process of the active substance; — for the finished product;— for an excipient	20/01/26
Vet - B12 a)	VNRA - Vet - B12 a) - - Vet - B12 a) - Minor changes:— to an approved test procedure — for active substance or a starting material, reagent or intermediate used in the manufacturing process of the active substance; — for the finished product;— for an excipient	20/01/26
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	25/02/25
Vet - G.I.2 b)	VRA-S - Vet - G.I.2 b) - b) Harmonisation of the generic/hybrid product according to article 71(1) after SPC harmonisation of the reference product - G.I.2 b) Safety, Efficacy, Pharmacovigilance changes - Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid medicinal product following assessment of the same change for the reference product - Harmonisation of the generic/hybrid product according to article 71(1) after SPC harmonisation of the reference product	25/02/25
Vet - F.I.b.2 b)	VRA-R - Vet - F.I.b.2 b) - b) Other changes to a test procedure (including replacement or addition) for the active substance - F.I.b.2 b) Quality Changes - Active Substance - Control of active substance - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Other changes to a test	24/02/25

	procedure (including replacement or addition) for the active substance	
Vet - F.I.d.1 c)	VRA-R - Vet - F.I.d.1 c) - c) Extension or introduction of a re-test period/storage period supported by real time data - F.I.d.1 c) Quality Changes - Active Substance - Stability - Change in the re-test period/storage period of the active substance where no Ph. Eur. Certificate of Suitability covering the retest period is part of the approved dossier - Extension or introduction of a re-test period/storage period supported by real time data	24/02/25
Vet - F.I.f.1	VRA-S - Vet - F.I.f.1 - 1. Substantial changes in the updated version of the ASMF or the active substance part of the dossier - F.I.f.1 Quality Changes - Active Substance - Other changes to the active substance - Substantial changes in the updated version of the ASMF or the active substance part of the dossier	24/02/25
Vet - B39	VNRA - Vet - B39 - Change in any part of the primary packaging material not in contact with the finished product formulation - B39 Changes to the quality part of the dossier: Change in any part of the primary packaging material not in contact with the finished product formulation (such as change of colour due to different plastic used for flip-off caps, colour code rings on ampoules or change of needle shield)	09/01/25
Vet - B21	VNRA - Vet - B21 - Replacement or addition of a secondary packaging site of a finished product - B21 Changes to the quality part of the dossier: Replacement or addition of a secondary packaging site of a finished product	09/01/25
Vet - F.II.e.1 b) 2.	VRA-S - Vet - F.II.e.1 b) 2. - b) Change in type of container or addition of a new container 2. Sterile medicinal products and biological/ immunological medicinal products - F.II.e.1 b) 2. Quality Changes - Container closure system - Change in immediate packaging of the finished product - Change in type of container or addition of a new container - Sterile medicinal products and biological/immunological medicinal products	20/05/24
Vet - F.II.b.3 a)	VRA-S - Vet - F.II.b.3 a) - a) Minor change in the manufacturing process - F.II.b.3 a) Quality Changes - Finished Product - Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Minor change in the manufacturing process	20/05/24
Vet - F.II.b.3 a)	VRA-S - Vet - F.II.b.3 a) - a) Minor change in the manufacturing process - F.II.b.3 a) Quality Changes - Finished Product - Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Minor change in the manufacturing process	20/05/24

Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	01/03/24
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	01/03/24
Vet - B3 d)	VNRA - Vet - B3 d) - d) Deletion of a non-significant specification parameter (active substance, starting material, intermediate - B3 d) Changes to the quality part of the dossier: Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) of — an active substance; — a starting material; —an intermediate or reagent used in the manufacturing process of the active substance	21/11/23
Vet - B44(Do not use)	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	21/11/23
Vet - B47 b)	VNRA - Vet - B47 b) - b) Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - B47 b) Changes to the quality part of the dossier: Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State: — change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State	21/11/23
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	06/06/23
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety,	03/10/22

	efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	
--	--	--